Related Experiment Videos
Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study
Insights
Hydralazine treatment in chronic congestive heart failure (CHF) patients showed significant improvements in symptoms and exercise capacity over 12 months. While mortality rates were similar, hydralazine demonstrated beneficial clinical effects in long-term management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic congestive heart failure (CHF) affects numerous patients, necessitating effective long-term treatment strategies.
- Conventional therapies for CHF often have limitations in improving patient outcomes and quality of life.
Purpose of the Study:
- To evaluate the long-term clinical efficacy of hydralazine when added to conventional therapy in patients with chronic congestive heart failure (CHF).
- To assess the impact of hydralazine on symptomatic improvement, exercise capacity, and radiographic findings in CHF patients.
Main Methods:
- A 12-month, placebo-controlled trial involving 62 patients with New York Heart Association class III CHF.
- Patients received either hydralazine (149 +/- 11 mg daily) or a placebo, in addition to their existing conventional therapy.
- Outcomes measured included mortality rates, symptomatic improvement, exercise capacity (watts), and chest x-ray examinations.
Main Results:
- No significant difference in 1-year mortality rates between the hydralazine (28%) and placebo (27%) groups.
- Hydralazine group showed a statistically significant, gradual increase in symptomatic improvement compared to placebo by month 12 (p < 0.05).
- Significant improvements in exercise capacity (25% increase, p < 0.01) and chest x-ray findings (p < 0.01) were observed in the hydralazine group, contrasting with deterioration in the placebo group (p < 0.05).
Conclusions:
- Hydralazine demonstrates beneficial clinical effects in the long-term treatment of chronic congestive heart failure (CHF).
- The addition of hydralazine to conventional therapy can lead to improved exercise tolerance and symptomatic relief in CHF patients.
- Further research may explore hydralazine's role in mitigating disease progression and improving radiographic outcomes in CHF.
Abstract:
In a placebo-controlled trial 62 patients with chronic congestive heart failure (CHF) (New York Heart Association class III) had hydralazine (149 +/- 11 mg daily) or placebo added to conventional therapy. During 12 months' follow-up 27 patients dropped out, 15 of 32 in the hydralazine group and 12 of 30 among the control subjects. The 1-year mortality rate was 28% in the hydralazine group compared to 27% in the control group. Symptomatic improvement was noted in both groups; however, it was gradually more pronounced in the actively treated group with a statistically significant difference between the two groups at month 12 (p less than 0.05). The hydralazine patients increased their exercise capacity 25%, from 53 +/- 3 watts at month 0 to 67 +/- 4 watts at month 12 (p less than 0.01). No improvement in exercise capacity took place in the placebo group. A significant improvement in chest x-ray examination was found with hydralazine (p less than 0.01) in contrast to a significant deterioration among the control subjects (p less than 0.05). Thus, we conclude that hydralazine used in chronic CHF has beneficial clinical effects during long-term treatment.